BetaAmyloid42 (ABeta42); Phosphorylated Tau 181 (pTau); Total Tau (Tau)
Back to Test Catalogue
Alzheimer’s Disease Biomarkers Panel, CSF
Test ID: ALZD CSF
Test
Method
Electrochemiluminescent immunoassays
Method Description
Elecsys® AD CSF assay
Platform
Roche cobas©
Report Includes
Specimens
CSF
Sample must be collected in a Sarstedt FB CSF Collection tube 63.614.625 (blue cap) tube.
These tubes can be ordered from In-Common Laboratories, using the Client Supply Request form.
Sample must be collected in a Sarstedt FB CSF Collection tube 63.614.625 (blue cap) tube.
These tubes can be ordered from In-Common Laboratories, using the Client Supply Request form.
Clinical Utility
Please refer to Roche Press Release.
Test Location
London Health Sciences Centre, 339 Windermere Road, London ON N6A 5A5
Test Version
27-Oct-2023
Specimen
Specimens
CSF
Sample must be collected in a Sarstedt FB CSF Collection tube 63.614.625 (blue cap) tube.
These tubes can be ordered from In-Common Laboratories, using the Client Supply Request form.
Sample must be collected in a Sarstedt FB CSF Collection tube 63.614.625 (blue cap) tube.
These tubes can be ordered from In-Common Laboratories, using the Client Supply Request form.
Collection Containers
Sarstedt 63.614.625 (blue cap) tube
Sample Volume
2.5 mL
Minimum Volume
1.5 mL
Collection & Handling
Collection Instructions
Specimens for Alzheimer’s Disease Biomarkers must be collected and handled as described in this downloadable document: Collection & Handling Instructions.
Note: CSF must be collected into the Sarstedt 63.614.625 (blue cap) tube.
β-amyloid peptides will adhere to plastics such as polystyrene. Failure to follow the recommended collection protocol may result in a falsely low Aβ42 result and contribute to an incorrect diagnosis of Alzheimer’s disease.
Handling Information
Specimens for Alzheimer’s Disease Biomarkers must be collected and handled as described in this downloadable document: Collection & Handling Instructions.
Stability
| Ambient | 12 hours |
|---|---|
| Refrigerated | 14 days |
| Frozen | 60 days |
Rejection Criteria
| Specimen | Not collected as described |
|---|
Test Version
27-Oct-2023
Performance / Interpretation
Method
Electrochemiluminescent immunoassays
Method Description
Elecsys® AD CSF assay
Platform
Roche cobas©
Turnaround Time
11 days
Results
| Name | Units | Reference Range | Conversion Factor | |
|---|---|---|---|---|
| BetaAmyloid42 (ABeta42) | pg/mL |
|
||
| Phosphorylated Tau 181 (pTau) | pg/mL |
|
||
| Total Tau (Tau) | pg/mL |
|
||
| pTau:ABeta42 Ratio |
|
|||
|
Compared to CSF concentrations of ABeta42, pTau, and Tau individually, the pTau/ABeta42 ratio has been shown to better correlate with Alzheimer's disease-related pathologic change as measured by amyloid PET scan.
Please note that improper specimen collection or handling technique may falsely decrease ABeta42 and increase the pTau/ABeta42 ratio. Discrepancies in interpretation of the pTau/ABeta42 ratio compared to CSF concentrations of ABeta42, pTau, and/or Tau individually may relate to improper specimen collection/handling, inter-individual variation in beta-amyloid CSF concentration, a disorder related to CSF dynamics, and/or elevation in pTau due to a non-Alzheimer's disease-related pathologic change. Clinical correlation is required. For patients with values near cutoffs, interpretation in the context of clinical history is particularly important. |
||||
Sample Reports
Test Location
London Health Sciences Centre, 339 Windermere Road, London ON N6A 5A5
Test Version
27-Oct-2023
Interface / Setup
HL7 Interface Codes
| Order Code | Result Codes | Units |
|---|---|---|
| ALZD CSF | 65228BetaAmyloid42 (ABeta42),CSF | pg/mL |
| 65229Phosphorylated Tau 181 (pTau),CSF | pg/mL | |
| 65230Total Tau (Tau),CSF | pg/mL | |
| 65231Alzheimer Interp (ABeta42,pTau,Tau),CSF | ||
| 65232pTau:ABeta42 Ratio,CSF | ||
| 65233Alzheimer Interp (pTau:ABeta42Ratio),CSF | ||
| 65234General Alzheimer's Comment,CSF |
Sample Reports
Test Version
27-Oct-2023